CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • AACR 2022 Recap: T Cells Still On Top, But Make Room for Myeloid Cells

    At the 2022 AACR annual meeting, CRI scientists highlighted a wide scope of cancer immunology advances, and…

    April 14, 2022| Arthur N. Brodsky, PhD
  • Head and Neck Cancer Awareness Month: 2022 Immunotherapy Research Updates

    This April for Head and Neck Cancer Awareness Month, discover the new research, new treatments, and progress…

    April 3, 2022| CRI Staff
  • Esophageal Cancer Awareness Month: 2022 Immunotherapy Research Updates

    This April for Esophageal Cancer Awareness Month, discover the new research, new treatments, and progress for a…

    April 2, 2022| CRI Staff
  • Ira Mellman Receives 2022 AACR-CRI Lloyd J. Old Award in Cancer Immunology

    Dr. Ira Mellman, a longtime member of the CRI Scientific Advisory Council, received CRI’s highest scientific career…

    April 1, 2022| Arthur N. Brodsky, PhD
  • AACR 2022 Preview: Decoding Cancer Complexity, Integrating Science, and Transforming Patient Outcomes

    During AACR’s upcoming 2022 annual meeting, CRI scientists will share the latest advances in cancer immunotherapy.

    April 1, 2022| Arthur N. Brodsky, PhD
  • FDA Immunotherapy Approvals in 2022

    As drug development in cancer immunotherapy has accelerated, the U.S. Food and Drug Administration has made several…

    March 30, 2022| CRI Staff
  • Mining the Mysteries of Myeloid Cells with CRI Lloyd J. Old STAR Malay Haldar

    CRI Lloyd J. Old STAR Malay Haldar is exploring the role of dendritic cells and macrophages in…

    March 28, 2022| Arthur N. Brodsky, PhD
  • FDA Approves New LAG-3 Checkpoint Inhibitor Immunotherapy Combination

    Patients with unresectable or metastatic melanoma can now be treated with dual checkpoint blockade targeting the PD-1…

    March 24, 2022| Max Mallet
  • Neutrophils and Inflammation in Colorectal Cancer with CRI Lloyd J. Old STAR Ivan Zanoni

    CRI Lloyd J. Old STAR Ivan Zanoni is exploring the multifaceted roles of neutrophils in colorectal cancer.

    March 21, 2022| Arthur N. Brodsky, PhD
Previous Page
1 … 18 19 20 21 22 … 91
Next Page
Father and son

Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

See ways to give

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute